PET Radiotracers for Molecular Imaging in Dementia
Aylin Baskin, Panteleimon Giannakopoulos, Osman Ratib, Yann Seimbille, Frederic Assal, Daniela Perani and Valentina Garibotto
Pages 215-230 (16)
Molecular imaging with various biomarkers plays a significant role in the diagnostic assessment of patients
with dementing disorders, by detecting functional and pathophysiologic changes in the brain. PET imaging, in particular,
allows the measurements of different molecular targets, such as functional markers of neurodegeneration (glucose metabolism),
markers for pathological aggregates (such as amyloid, tau and synuclein aggregates) and neuroinflammation,
and also markers of several neurotransmission systems. In the current view, neurodegenerative diseases are associated
with the development of pathologic changes that play a different role in disease onset and evolution, often starting long
before the onset of clinically detectable impairment. Molecular imaging represents thus a unique tool to collect relevant
information contributing to accurate diagnosis, treatment and response monitoring. In this article, we review the current
literature focusing on the PET radiotracers used for molecular imaging in dementia.
Dementia, biomarkers, glucose metabolism, amyloid, tau protein, synuclein, neurotransmission.
Nuclear Medicine Division, Department of Medical Imaging, Geneva University Hospital, Rue Gabrielle- Perret-Gentil 4, 1211 Genève 14, Switzerland.